KR102551499B1 - Composition for the prevention or treatment of SARS-CoV-2 infection, comprising the extract of Agrimonia pilosa as an active ingredient - Google Patents
Composition for the prevention or treatment of SARS-CoV-2 infection, comprising the extract of Agrimonia pilosa as an active ingredient Download PDFInfo
- Publication number
- KR102551499B1 KR102551499B1 KR1020210049299A KR20210049299A KR102551499B1 KR 102551499 B1 KR102551499 B1 KR 102551499B1 KR 1020210049299 A KR1020210049299 A KR 1020210049299A KR 20210049299 A KR20210049299 A KR 20210049299A KR 102551499 B1 KR102551499 B1 KR 102551499B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cov
- sars
- yongacho
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 239000004480 active ingredient Substances 0.000 title claims description 19
- 238000011282 treatment Methods 0.000 title claims description 17
- 208000025721 COVID-19 Diseases 0.000 title claims description 10
- 208000037847 SARS-CoV-2-infection Diseases 0.000 title claims description 9
- 230000002265 prevention Effects 0.000 title claims description 8
- 241001278836 Agrimonia pilosa Species 0.000 title description 7
- 235000000641 Agrimonia pilosa Nutrition 0.000 title description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 36
- 230000036541 health Effects 0.000 claims description 22
- 235000013376 functional food Nutrition 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 18
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 18
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 18
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 18
- 235000005875 quercetin Nutrition 0.000 claims description 18
- 229960001285 quercetin Drugs 0.000 claims description 18
- 229940096998 ursolic acid Drugs 0.000 claims description 18
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 16
- 230000010076 replication Effects 0.000 claims description 11
- 206010037660 Pyrexia Diseases 0.000 claims description 9
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 230000001603 reducing effect Effects 0.000 claims description 2
- 241001678559 COVID-19 virus Species 0.000 claims 3
- 241000711573 Coronaviridae Species 0.000 abstract description 31
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000003449 preventive effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 230000036760 body temperature Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002962 plaque-reduction assay Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- -1 pH regulators Substances 0.000 description 5
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229940096437 Protein S Drugs 0.000 description 4
- 101710198474 Spike protein Proteins 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960002328 chloroquine phosphate Drugs 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003032 molecular docking Methods 0.000 description 4
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 4
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001164374 Calyx Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000157072 Hylocereus undatus Species 0.000 description 2
- 235000018481 Hylocereus undatus Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017826 Gastric ulcer haemorrhage Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 용아초 추출물의 코로나 바이러스 감염에 대한 예방, 개선 또는 치료 효과를 확인하여 용아초 추출물을 이용하여 코로나 바이러스를 예방 또는 치료할 수 있는 조성물을 제조하는 것을 목적으로 한다.An object of the present invention is to prepare a composition capable of preventing or treating corona virus using the extract of Yongacho by confirming the preventive, ameliorative or therapeutic effect of the extract of Yongacho on coronavirus infection.
Description
본 발명은 용아초(Agrimonia pilosa) 추출물을 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, improving or treating coronavirus infection (SARS-CoV-2) comprising an extract of Agrimonia pilosa as an active ingredient.
현재 전세계적으로 문제되고 있는 코로나 바이러스는 SARS-CoV-2 감염에 의한 호흡기 증후군이라 정의되고 있으며, 질병 분류는 법정감염병 제1급감염병 신종감염병증후군 및 질병 코드는 U07.1이다. 병원체는 SARS-CoV-2 : Coronaviridae에 속하는 RNA 바이러스이고, 전파 경로는 현재까지 비말(침방울), 접촉을 통한 전파로 알려져있다. 따라서, 기침이나 재채기를 할 때 생긴 비말(침방울)을 통한 전파 등 또는 코로나19 바이러스에 오염된 물건을 만진 뒤 눈, 코, 입을 만짐으로써 전파되고 있다고 알려져 있다. 전세계 치명률은 약 3.4%(WHO, 3.5 기준)이고, 단 국가별 · 연령별 치명률 수준은 매우 상이하다. 고령, 면역기능이 저하된 환자, 기저질환을 가진 환자가 주로 중증, 사망을 초래한다.Corona virus, which is currently a problem worldwide, is defined as respiratory syndrome caused by SARS-CoV-2 infection, and the disease classification is the first class infectious disease, the new infectious disease syndrome, and the disease code is U07.1. The pathogen is SARS-CoV-2: an RNA virus belonging to Coronaviridae, and the transmission route is known to be spread through droplets (saliva droplets) and contact. Therefore, it is known that it is transmitted through droplets (saliva droplets) produced when coughing or sneezing, or by touching objects contaminated with the Corona 19 virus and then touching the eyes, nose, or mouth. The global fatality rate is about 3.4% (WHO, 3.5 standard), but the fatality rate level varies greatly by country and age. Elderly, immunocompromised patients, and patients with underlying diseases mainly cause severe illness and death.
코로나 바이러스의 잠복기는 1~14일(평균 4~7일)이고, 진단 기준으로는 진단을 위한 검사기준에 따라 감염병병원체 감염이 확인된 사람의 검체에서 바이러스 분리 또는 검체에서 특이 유전자 검출하여 진단하고 있다. 코로나 바이러스의 증상으로는 발열, 권태감, 기침, 호흡곤란 및 폐렴 등 경증에서 중증까지 다양한 호흡기감염증이 나타나며, 그 외 가래, 인후통, 두통, 객혈과 오심, 설사 등도 나타난다. 현재 수액 보충, 해열제 등 보존적 치료를 하는 것 외에 특이적인 항바이러스제가 없는 것이 현실이다.The incubation period of coronavirus is 1 to 14 days (average 4 to 7 days), and the diagnosis criteria is to isolate the virus from a sample of a person confirmed to be infected with an infectious disease pathogen according to the test criteria for diagnosis or to diagnose by detecting a specific gene in the sample there is. Symptoms of coronavirus include fever, malaise, cough, shortness of breath, pneumonia, and various respiratory infections ranging from mild to severe, as well as phlegm, sore throat, headache, hemoptysis, nausea, and diarrhea. Currently, there is no specific antiviral agent other than conservative treatment such as fluid supplementation and antipyretics.
한편, 용아초(Agrimonia pilosa)는 한국, 일본, 중국, 인도 등지에 분포하는 여러해살이풀이다. 이는 짚신나물 또는 선학초라고도 불린다. 굵은 뿌리줄기에 줄기가 나오고 높이 30~100cm이며 전체에 털이 있다. 잎은 어긋나고 우상복엽이며 작은잎은 5~7개로 타원형이고 가장자리에 톱니가 있다. 끝에 달린 3개의 작은잎은 크기가 비슷하고 작은잎 사이에 작은잎 같은 것이 달린다. 꽃은 6~8월에 피고 황색이며 총상꽃차례에 달린다. 꽃받침 통은 길이 3mm 정도이고 세로줄이 있으며 위 끝이 5개로 갈라진다. 꽃잎은 5개, 수술은 12개이며 열매는 꽃받침통 안에 들어 있다. 어린순을 나물로 하고 한방에서 선초를 이질, 위궤양, 자궁출혈에 사용한다. 용아초를 자세히 살펴보면, 갈고리 같은 털들이 있다. 사람들의 옷이나 신발에 잘 달라붙는 성향이 있어 짚신에 붙어 이곳저곳을 붙어 다녔다는 데서 '짚신나물'이라는 이름이 유래되었다.Meanwhile, Agrimonia pilosa is a perennial plant distributed in Korea, Japan, China, and India. It is also called strawsinnamul or seonhakcho. The stem comes out on the thick rhizome, it is 30~100cm high, and there are hairs all over. Leaves are alternate, pinnately leafy, with 5 to 7 small leaves, elliptical, with sawtooth on the edge. The three small leaves attached to the end are similar in size, and there is a small leaf-like thing between the small leaves. Flowers bloom in June-August, are yellow, and hang on raceme. The calyx tube is about 3mm long, has vertical lines, and the upper end is split into 5 pieces. There are 5 petals and 12 stamens, and the fruit is contained in the calyx tube. Young shoots are used as herbs, and in oriental medicine, Seoncho is used for dysentery, gastric ulcer, and uterine bleeding. If you look closely at the dragon acho, there are hook-like hairs. It has a tendency to stick to people's clothes or shoes, so the name 'Jipsinnamul' was derived from the fact that it stuck to straw sandals and stuck here and there.
따라서, 본 발명은 용아초 추출물을 유효성분으로 하여, 코로나 바이러스를 예방, 개선 또는 치료할 수 있는 조성물에 관한 것으로서, 용아초 추출물을 사용하여 SARS-CoV-2 바이러스에 대한 플라크 감소 실험을 진행한 결과 농도의존적으로 유의적인 결과를 확인하였다. 또한, SARS-CoV-2의 spike protein(스파이크 단백질)의 RNA 복제억제 실험을 진행한 결과 매우 우수하게 바이러스의 복제를 억제함을 확인하였다. 따라서, 용아초 추출물은 SARS-CoV-2의 RNA복제를 억제하여 코로나 바이러스를 억제하는 것으로 나타났다. 이를 통하여 고농도에서 독성이 없으면서 치료효과가 우수한 코로나 바이러스 감염의 예방 또는 개선용 조성물의 개발이 가능할 것이며, 이를 통하여 코로나 바이러스의 예방 또는 개선용 조성물로서 추가 연구를 통해 건강기능식품 또는 의약품으로 개발 가능할 것이다.Therefore, the present invention relates to a composition capable of preventing, improving, or treating corona virus using an extract of yongsacho as an active ingredient. Significant results were confirmed in a concentration-dependent manner. In addition, as a result of the RNA replication inhibition experiment of the spike protein of SARS-CoV-2, it was confirmed that the virus replication was inhibited very well. Therefore, it was shown that the extract of Yongacho suppresses the corona virus by inhibiting the RNA replication of SARS-CoV-2. Through this, it will be possible to develop a composition for preventing or improving corona virus infection that is non-toxic at high concentration and has excellent therapeutic effect, and through this, it will be possible to develop a composition for preventing or improving corona virus as a health functional food or medicine through additional research. .
본 발명의 목적은, 용아초(Agrimonia pilosa) 추출물을 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 개선용 건강기능식품 조성물을 제공하는 것이다.An object of the present invention is to provide a health functional food composition for preventing or improving corona virus (SARS-CoV-2) infection comprising an extract of Agrimonia pilosa as an active ingredient.
또한, 본 발명의 다른 목적은 용아초(Agrimonia pilosa) 추출물을 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.In addition, another object of the present invention is to provide a pharmaceutical composition for preventing or treating corona virus (SARS-CoV-2) infection comprising an extract of Agrimonia pilosa as an active ingredient.
또한, 용아초에서 분리된 우르솔산(ursolic acid) 또는 케르세틴(quercetin)를 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.In addition, to provide a pharmaceutical composition for the prevention or treatment of coronavirus (SARS-CoV-2) infection comprising ursolic acid or quercetin isolated from yong-a-cho as an active ingredient.
즉, 본 발명은 용아초 추출물 또는 이로부터 분리된 우르솔산(ursolic acid) 또는 케르세틴(quercetin)를 이용하여 코로나 바이러스(SARS-CoV-2) 감염에 대한 예방, 개선 또는 치료 효과를 확인하고, 이를 통해 용아초추출물 또는 우르솔산(ursolic acid) 또는 케르세틴(quercetin)를 이용한 코로나 바이러스(SARS-CoV-2)를 예방, 개선 또는 치료할 수 있는 건강기능식품 또는 의약품으로 사용 가능한 조성물을 제조하는 것을 목적으로 한다.That is, the present invention confirms the preventive, ameliorative, or therapeutic effect on corona virus (SARS-CoV-2) infection using the dragon plant extract or ursolic acid or quercetin isolated therefrom, For the purpose of preparing a composition that can be used as a health functional food or medicine that can prevent, improve, or treat corona virus (SARS-CoV-2) using a dragon plant extract or ursolic acid or quercetin through do.
상기 과제를 해결하기 위하여, 본 발명은 용아초 추출물을 유효성분으로 포함하는, 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In order to solve the above problems, the present invention provides a health functional food composition for preventing or improving corona virus (SARS-CoV-2) infection, including a yongacho extract as an active ingredient.
본 발명의 일 실시예에 있어서, 본 발명의 ‘용아초 추출물’은 물, C1 내지 C4의 알코올, 에틸아세테이트, 클로로포름 및 헥산 중에서 선택된 적어도 어느 하나의 용매로 추출된 것일 수 있고, 바람직하게는 30 내지 70% 에탄올을 사용하여 추출된 것일 수 있으며, 더욱 바람직하게는 50% 에탄올을 사용하여 추출된 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the 'Yongacho extract' of the present invention is water, C 1 to It may be extracted with at least one solvent selected from C 4 alcohol, ethyl acetate, chloroform and hexane, preferably extracted using 30 to 70% ethanol, more preferably 50% ethanol It may be extracted using, but is not limited thereto.
본 발명의 일 실시예에 있어서, 본 발명의 ‘코로나 바이러스’는 베타-코로나 바이러스일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the 'corona virus' of the present invention may be a beta-corona virus, but is not limited thereto.
본 발명의 일 실시예에 있어서, 본 발명의 ‘용아초 추출물’은 코로나 바이러스(SARS-CoV-2)에 대한 플라크 감소 효과를 가지는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the 'Yongacho extract' of the present invention may have a plaque reducing effect against coronavirus (SARS-CoV-2), but is not limited thereto.
본 발명의 일 실시예에 있어서, 본 발명의 ‘용아초 추출물’은 코로나 바이러스(SARS-CoV-2) 복제를 억제시키는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the 'Yongacho extract' of the present invention may be to inhibit the replication of coronavirus (SARS-CoV-2), but is not limited thereto.
본 발명의 일 실시예에 있어서, 본 발명의 ‘용아초 추출물’은 우르솔산(ursolic acid) 또는 케르세틴(quercetin) 성분을 포함하는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the 'Yongacho extract' of the present invention may contain ursolic acid or quercetin, but is not limited thereto.
본 발명의 일 실시예에 있어서, 본 발명의 ‘용아초 추출물’은 코로나 바이러스로 인한 발열을 억제하는 효과를 가지는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the 'Yongacho extract' of the present invention may have an effect of suppressing fever due to corona virus, but is not limited thereto.
본 발명의 일 실시예에 있어서, 본 발명의 ‘조성물’은 코로나 바이러스 스파이크 단백질의 세포막 결합을 차단하여 감염을 억제하는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the 'composition' of the present invention may inhibit infection by blocking the cell membrane binding of the coronavirus spike protein, but is not limited thereto.
또한, 본 발명은 용아초 추출물을 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of coronavirus (SARS-CoV-2) infection comprising an extract of yongsacho as an active ingredient.
또한, 본 발명은 용아초에서 분리된 우르솔산(ursolic acid) 또는 케르세틴(quercetin)를 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating corona virus (SARS-CoV-2) infection comprising ursolic acid or quercetin isolated from yongsacho as an active ingredient.
2002년 유행한 사스(SARS), 2012년 유행한 메르스(MERS), 그리고 2020년 시작하여 지금까지 유행하고 있는 SARS-CoV2(Covid-19)까지 다양한 코로나 바이러스에 의하여 전세계적으로 많은 사람이 사망하였다. 또한, 코로나 바이러스는 RNA 바이러스의 특성상 돌연변이가 쉽게 일어나기 쉽기 때문에 변형된 코로나 바이러스가 발생될 확률이 높다. 따라서 본 발명에 따른, 천연물인 용아초 추출물을 사용하여 SARS-CoV-2 바이러스에 대한 플라크 감소 실험을 진행한 결과 농도의존적으로 유의적인 결과를 확인하였다. 또한, SARS-CoV-2의 spike protein(스파이크 단백질)의 RNA 복제억제 실험을 진행한 결과 매우 우수하게 바이러스의 복제를 억제하였다. 따라서, 용아초 추출물은 SARS-CoV-2의 RNA복제를 억제하여 코로나 바이러스를 억제하는 효과를 확인하여 본 발명을 완성하였다.Many people around the world die from various coronaviruses, including the SARS epidemic in 2002, MERS epidemic in 2012, and SARS-CoV2 (Covid-19), which has been prevalent since 2020. did In addition, since coronaviruses are prone to mutations due to the nature of RNA viruses, there is a high probability that modified corona viruses will occur. Therefore, as a result of conducting a plaque reduction experiment for the SARS-CoV-2 virus using the natural product Yongacho extract according to the present invention, significant results were confirmed in a concentration-dependent manner. In addition, as a result of the RNA replication inhibition experiment of the spike protein of SARS-CoV-2, the replication of the virus was inhibited very well. Therefore, the present invention was completed by confirming the effect of inhibiting the corona virus by inhibiting RNA replication of SARS-CoV-2.
도 1은 본 발명의 용아초 추출물을 이용하여 플라크 감소 분석을 실험하여 결과를 나타낸 도이다.
도 2는 본 발명의 용아초 추출물을 이용하여 플라크 감소 분석을 실험하여 결과를 나타낸 도이다.
도 3은 본 발명의 용아초 추출물을 이용하여 플라크 감소 분석을 실험하여 결과를 나타낸 도이다.
도 4는 본 발명의 용아초 추출물을 이용하여 플라크 감소 분석을 실험하여 결과를 나타낸 도이다.
도 5는 본 발명의 용아초 추출물을 이용하여 용아초 추출물의 바이러스 복제억제 실험하여 결과를 나타낸 도이다.
도 6은 본 발명의 용아초 성분인 우르솔산(ursolic acid) 및 케르세틴(quercetin)을 이용하여 플라크감소 분석을 실험하여 결과를 나타낸 도이다.
도 7은 본 발명의 용아초 성분인 우르솔산(ursolic acid) 및 케르세틴(quercetin)과 SARS-CoV-2 spike RBD의 molecular docking을 분석하여 나타낸 도이다.
도 8은 본 발명의 용아초 추출물을 이용하여 체온 상승 유발물질(LPS)에 의한 발열에 대한 해열효과를 실험하여 나타낸 도이다.1 is a diagram showing the results of the plaque reduction assay using the yongacho extract of the present invention.
Figure 2 is a diagram showing the results of the plaque reduction assay using the yongacho extract of the present invention.
Figure 3 is a diagram showing the results of the plaque reduction assay using the yongacho extract of the present invention.
Figure 4 is a diagram showing the results of the plaque reduction assay using the yongacho extract of the present invention.
Figure 5 is a diagram showing the results of the virus replication inhibition test of the yongacho extract using the yongacho extract of the present invention.
Figure 6 is a diagram showing the results of an experiment for plaque reduction assay using ursolic acid and quercetin, which are components of dragon grass of the present invention.
Figure 7 is a diagram showing the analysis of molecular docking of ursolic acid and quercetin, which are components of the present invention, and SARS-CoV-2 spike RBD.
Figure 8 is a diagram showing the antipyretic effect on the fever caused by the increase in body temperature inducing substance (LPS) tested by using the yongacho extract of the present invention.
이하, 첨부된 도면을 참조하여 본 발명의 실시예로 본 발명을 상세히 설명하기로 한다. 다만, 하기 실시예는 본 발명에 대한 예시로 제시되는 것으로, 당업자에게 주지 저명한 기술 또는 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명을 생략할 수 있고, 이에 의해 본 발명이 제한되지는 않는다. 본 발명은 후술하는 특허 청구범위의 기재 및 그로부터 해석되는 균등 범주 내에서 다양한 변형 및 응용이 가능하다.Hereinafter, the present invention will be described in detail by embodiments of the present invention with reference to the accompanying drawings. However, the following examples are presented as examples of the present invention, and if it is determined that detailed descriptions of well-known techniques or configurations may unnecessarily obscure the gist of the present invention, the detailed descriptions may be omitted. , the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the description of the claims described later and equivalent scopes interpreted therefrom.
또한, 본 명세서에서 사용되는 용어(terminology)들은 본 발명의 바람직한 실시예를 적절히 표현하기 위해 사용된 용어들로서, 이는 사용자, 운용자의 의도 또는 본 발명이 속하는 분야의 관례 등에 따라 달라질 수 있다. 따라서, 본 용어들에 대한 정의는 본 명세서 전반에 걸친 내용을 토대로 내려져야 할 것이다. 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함"한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성 요소를 더 포함할 수 있는 것을 의미한다.In addition, the terms used in this specification (terminology) are terms used to appropriately express preferred embodiments of the present invention, which may vary according to the intention of a user or operator or customs in the field to which the present invention belongs. Therefore, definitions of these terms will have to be made based on the content throughout this specification. Throughout the specification, when a certain component is said to "include", it means that it may further include other components without excluding other components unless otherwise stated.
본 명세서 전체에 걸쳐, 특정 물질의 농도를 나타내기 위하여 사용되는 '%'는 별도의 언급이 없는 경우, 고체/고체는(w/w) %, 고체/액체는(w/v) %, 그리고 액체/액체는(v/v) %이다.Throughout this specification, '%' used to indicate the concentration of a particular substance is solid/solid (w/w) %, solid/liquid (w/v) %, and Liquid/liquid is (v/v) %.
본 발명에서 사용되는 모든 기술용어는, 달리 정의되지 않는 이상, 본 발명의 관련 분야에서 통상의 당업자가 일반적으로 이해하는 바와 같은 의미로 사용된다. 또한 본 명세서에는 바람직한 방법이나 시료가 기재되나, 이와 유사하거나 동등한 것들도 본 발명의 범주에 포함된다. 본 명세서에 참고문헌으로 기재되는 모든 간행물의 내용은 본 발명에 도입된다.All technical terms used in the present invention, unless defined otherwise, are used with the same meaning as commonly understood by one of ordinary skill in the art related to the present invention. In addition, although preferred methods or samples are described in this specification, those similar or equivalent thereto are also included in the scope of the present invention. The contents of all publications incorporated herein by reference are incorporated herein by reference.
일 측면에서, 본 발명은 용아초 추출물을 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 개선용 건강기능식품 조성물을 제공하는 것을 목적으로 한다.In one aspect, an object of the present invention is to provide a health functional food composition for preventing or ameliorating corona virus (SARS-CoV-2) infection, including an extract of yongsacho as an active ingredient.
본 발명에 따른 추출물은 당업계에 공지된 추출 및 분리방법을 사용하여 천연 용아초로부터 추출 및 분리하여 수득한 것을 사용할 수 있으며, 본 발명에서 정의된 “추출물”은 적절한 용매를 이용하여 용아초로부터 추출한 것이며, 예를 들어, 조추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함한다. 상기 용아초로부터 추출물을 추출하기 위한 적절한 용매로는 약학적으로 허용되는 유기용매라면 어느 것을 사용해도 무방하며, 물 또는 유기용매를 사용할 수 있으며, 이에 제한되지는 않으나, 예를 들어, 정제수, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등을 포함하는 탄소수 1 내지 4의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane) 및 시클로헥산(cyclohexane) 등의 각종 용매를 단독으로 혹은 혼합하여 사용할 수 있고, 바람직하게는 에탄올 30 내지 70%를 용매로 사용하였으며, 더욱 바람직하게는 에탄올 50%를 용매로 사용하였다. 추출 방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 어느 하나를 선택하여 사용할 수 있다. 또한, 목적하는 추출물은 추가로 통상의 분획 공정을 수행할 수도 있으며, 통상의 정제 방법을 이용하여 정제될 수도 있다.The extract according to the present invention may be obtained by extracting and separating from natural dragon acho using an extraction and separation method known in the art, and the "extract" defined in the present invention is from dragon acho using an appropriate solvent. It is extracted, and includes, for example, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract. Any suitable solvent for extracting the extract from the dragon acho may be used as long as it is a pharmaceutically acceptable organic solvent, and water or an organic solvent may be used, but is not limited thereto, for example, purified water, methanol (methanol), ethanol, propanol, isopropanol, alcohol having 1 to 4 carbon atoms including butanol, acetone, ether, benzene, chloroform Various solvents such as (chloroform), ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination, preferably 30 to 70% ethanol. was used as a solvent, more preferably 50% ethanol was used as a solvent. As an extraction method, any one of methods such as hot water extraction, cold brew extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression may be selected and used. In addition, the desired extract may be additionally subjected to a conventional fractionation process or may be purified using a conventional purification method.
본 발명의 추출물의 제조방법에는 제한이 없으며, 공지되어있는 어떠한 방법도 이용될 수 있다. 예를 들면, 본 발명의 조성물에 포함되는 추출물은 상기한 열수 추출 또는 용매 추출법으로 추출된 1차 추출물을, 감압 증류 및 동결건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말상태로 제조할 수 있다. 또한 상기 1차 추출물을 실리카 겔 컬럼 크로마토그래피(silica gel column chromatography), 박층 크로마토그래피(thin layer chromatography), 고성능 액체 크로마토그래피(high performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 이용하여 추가로 정제된 분획을 얻을 수도 있다. 따라서 본 발명에 있어서 추출물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출액, 분리된 화합물, 분획 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함하는 개념이다.There is no limitation on the preparation method of the extract of the present invention, and any known method may be used. For example, the extract included in the composition of the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and lyophilization or spray drying of the primary extract extracted by the above-described hot water extraction or solvent extraction method. In addition, a fraction further purified from the primary extract using various chromatography methods such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography. can also be obtained. Therefore, in the present invention, the extract is a concept that includes all extracts, separated compounds, fractions, and purified products obtained in each step of extraction, fractionation, or purification, and dilutions, concentrates, or dried products thereof.
본 발명의 용아초 추출물을 건강기능식품 조성물로 사용하는 경우, 상기 용아초 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용할 수 있고, 통상의 방법에 따라 적절하게 사용할 수 있다. 상기 조성물은 유효성분 이외에 식품학적으로 허용가능한 식품보조첨가제를 포함할 수 있으며, 유효성분의 혼합량은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다.In the case of using the extract of Yongacho of the present invention as a health functional food composition, the extract of Yongacho may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. In addition to the active ingredient, the composition may include food additives acceptable in food science, and the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
본 발명에서 사용되는 용어 "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 본 발명의 식품보조첨가제의 종류가 제한되는 것은 아니다.The term "food supplement additive" used in the present invention refers to a component that can be added to food supplementally, and can be appropriately selected and used by those skilled in the art as being added to prepare a health functional food of each formulation. Examples of food additives include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners , pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc. are included, but the types of food additives of the present invention are not limited by the above examples.
본 발명의 식품 조성물에는 건강기능식품이 포함될 수 있다. 본 발명에서 사용되는 용어 "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 '기능성'이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 통상의 기술분야에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조시에는 통상의 기술분야에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한없이 제조될 수 있다. 본 발명의 식품용 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 앙염증 효과를 증진시키기 위한 보조제로 섭취가 가능하다.The food composition of the present invention may include health functional food. The term "health functional food" used in the present invention refers to food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functionalities for the human body. Here, 'functionality' means obtaining useful effects for health purposes, such as adjusting nutrients for the structure and function of the human body or physiological functions. The health functional food of the present invention can be manufactured by a method commonly used in the conventional technical field, and can be prepared by adding raw materials and components commonly added in the conventional technical field at the time of manufacture. In addition, the formulation of the health functional food may also be manufactured without limitation as long as the formulation is recognized as a health functional food. The composition for food of the present invention can be prepared in various types of formulations, and unlike general drugs, it has the advantage of not having side effects that can occur when taking drugs for a long time by using food as a raw material, and has excellent portability. Of the health functional foods can be taken as supplements to enhance the anti-inflammatory effect.
또한, 본 발명의 조성물이 사용될 수 있는 건강식품의 종류에는 제한이 없다. 아울러 본 발명의 용아초 추출물을 유효성분으로 포함하는 조성물은 당업자의 선택에 따라 건강기능식품에 함유될 수 있는 적절한 기타 보조 성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림 류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 추출물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다.In addition, there is no limitation on the type of health food in which the composition of the present invention can be used. In addition, the composition containing the extract of Yongacho of the present invention as an active ingredient can be prepared by mixing suitable other auxiliary ingredients that can be contained in health functional foods and known additives according to the selection of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There are vitamin complexes, etc., and it can be prepared by adding the extract according to the present invention to juice, tea, jelly, juice, etc. prepared as a main component.
이하 본 발명의 용아초 추출물을 유효성분으로 포함하는, 코로나 바이러스 감염의 예방 또는 개선용 건강기능식품의 제조예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, an example of manufacturing a health functional food for preventing or improving corona virus infection, including the extract of Yongacho of the present invention as an active ingredient, will be described, but the present invention is not intended to be limited to this, but only to be specifically described.
<제조예 1><Production Example 1>
용아초 추출물 200 ㎎Dragon Seed Extract 200 mg
비타민 A 아세테이트 70 ㎍Vitamin A Acetate 70 μg
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B 1 0.13 ㎎
비타민 B 2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B 6 0.5㎎
비타민 B 12 0.2 ㎍Vitamin B 12 0.2 μg
비타민 C 10 ㎎Vitamin C 10 mg
비오틴10 ㎍Biotin 10 μg
니코틴산아미드 1.7 ㎎Nicotinamide 1.7 mg
엽산 50 ㎍
판토텐산 칼슘 0.5 ㎎Calcium Pantothenate 0.5 mg
황산제1철 1.75 ㎎Ferrous sulfate 1.75 mg
산화아연 0.82 ㎎Zinc Oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium Carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium Phosphate Monobasic 15 mg
제2인산칼슘 55 ㎎Dibasic Calcium Phosphate 55 mg
구연산칼륨 90 ㎎Potassium Citrate 90 mg
탄산칼슘 100 ㎎
염화마그네슘 24.8 ㎎Magnesium Chloride 24.8 mg
일 측면에서, 본 발명은 용아초 추출물을 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 치료용 약학적 조성물 또는 용아초에서 분리된 우르솔산(ursolic acid) 또는 케르세틴(quercetin)를 유효성분으로 포함하는 코로나 바이러스(SARS-CoV-2) 감염의 예방 또는 치료용 약학적 조성물을 제공하는 것을 목적으로 한다.In one aspect, the present invention provides a pharmaceutical composition for the prevention or treatment of coronavirus (SARS-CoV-2) infection comprising an extract of dragon fruit as an active ingredient, or ursolic acid or quercetin isolated from dragon fruit. ) as an active ingredient to provide a pharmaceutical composition for preventing or treating coronavirus (SARS-CoV-2) infection.
본 발명에서 사용된 용어 "치료"란 본 발명의 조성물의 투여로 코로나 바이러스 감염, 바람직하게는 코로나 바이러스(SARS-CoV-2) 감염의 증세를 호전시키거나 이롭게 변경하는 모든 행위를 의미한다. 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자라면, 대한의학협회 등에서 제시된 자료를 참조하여 본 발명의 조성물이 효과가 있는 질환의 정확한 기준을 알고, 개선, 향상 및 치료된 정도를 판단할 수 있을 것이다.The term "treatment" as used herein refers to any action that improves or beneficially alters the symptoms of coronavirus infection, preferably coronavirus (SARS-CoV-2) infection, by administration of the composition of the present invention. Those of ordinary skill in the art to which the present invention belongs can know the exact criteria of the disease for which the composition of the present invention is effective, and determine the degree of improvement, improvement, and treatment by referring to the data presented by the Korean Medical Association. There will be.
일 구현예에서, 상기 약학 조성물은 경구형 제형, 외용제, 좌제, 멸균 주사용액 및 분무제를 포함하는 군으로부터 선택되는 하나 이상의 제형일 수 있으며, 주사 제형이 더욱 바람직하다.In one embodiment, the pharmaceutical composition may be one or more formulations selected from the group consisting of oral formulations, external preparations, suppositories, sterile injection solutions and sprays, and an injection formulation is more preferred.
본 발명에서, 용어 "예방"이란 본 발명에 따른 약학적 조성물의 투여에 의해 코로나 바이러스 감염, 바람직하게는 코로나 바이러스(SARS-CoV-2) 감염의 발생, 확산 및 재발을 억제 또는 지연시키는 모든 행위를 의미한다.In the present invention, the term "prevention" refers to all activities that suppress or delay the occurrence, spread, and recurrence of coronavirus infection, preferably coronavirus (SARS-CoV-2) infection, by administration of the pharmaceutical composition according to the present invention. means
본 발명에서 유효성분과 결합하여 사용된 "치료학적으로 유효한 양"이란 용어는 대상 질환을 예방 또는 치료하는데 유효한 조성물의 약학적으로 허용가능한 염의 양을 의미하며, 본 발명의 조성물의 치료적으로 유효한 양은 여러 요소, 예를 들면 투여방법, 목적부위, 환자의 상태 등에 따라 달라질 수 있다. 따라서, 인체에 사용 시 투여량은 안전성 및 효율성을 함께 고려하여 적정량으로 결정되어야 한다. 동물실험을 통해 결정한 유효량으로부터 인간에 사용되는 양을 추정하는 것도 가능하다. 유효한 양의 결정시 고려할 이러한 사항은, 예를 들면 Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; 및 E.W. Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.에 기술되어있다.The term "therapeutically effective amount" used in combination with an active ingredient in the present invention refers to an amount of a pharmaceutically acceptable salt of a composition effective for preventing or treating a target disease, and a therapeutically effective amount of the composition of the present invention It may vary depending on various factors, such as the method of administration, the target site, and the condition of the patient. Therefore, when used in the human body, the dosage should be determined in an appropriate amount considering both safety and efficiency. It is also possible to estimate the amount to be used in humans from the effective amount determined through animal experiments. These considerations in determining effective amounts are discussed, for example, in Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and E.W. Martin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에서 사용되는 용어, "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미하며, 유효용량 수준은 환자의 건강상태, 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여, 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means an amount that is sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and does not cause side effects, and the effective dose level is the patient's Health condition, type and severity of disease, activity of drug, sensitivity to drug, method of administration, time of administration, route of administration and excretion rate, duration of treatment, factors including drugs used in combination or concurrently, and other factors well known in the medical field can be determined according to The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. Considering all of the above factors, it is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by those skilled in the art.
본 발명의 약학 조성물은 약제학적으로 허용 가능한 첨가제를 더 포함할 수 있으며, 이때 약제학적으로 허용 가능한 첨가제로는 전분, 젤라틴화 전분, 미결정셀룰로오스, 유당, 포비돈, 콜로이달실리콘디옥사이드, 인산수소칼슘, 락토스, 만니톨, 엿, 아라비아고무, 전호화전분, 옥수수전분, 분말셀룰로오스, 히드록시프로필셀룰로오스, 오파드라이, 전분글리콜산나트륨, 카르나우바 납, 합성규산알루미늄, 스테아린산, 스테아린산마그네슘, 스테아린산알루미늄, 스테아린산칼슘, 백당, 덱스트로스, 소르비톨 및 탈크 등이 사용될 수 있다. 본 발명에 따른 약제학적으로 허용 가능한 첨가제는 상기 조성물에 대해 0.1 중량부 내지 90 중량부 포함되는 것이 바람직하나, 이에 한정되는 것은 아니다.The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additive includes starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, Lactose, Mannitol, Taffy, Gum Arabic, Pregelatinized Starch, Corn Starch, Powdered Cellulose, Hydroxypropyl Cellulose, Opadry, Sodium Starch Glycolate, Carnauba Lead, Synthetic Aluminum Silicate, Stearic Acid, Magnesium Stearate, Aluminum Stearate, Stearic Acid Calcium, white sugar, dextrose, sorbitol, and talc may be used. The pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 part by weight to 90 parts by weight based on the composition, but is not limited thereto.
본 발명의 조성물은 또한 생물학적 제제에 통상적으로 사용되는 담체, 희석제, 부형제 또는 둘 이상의 이들의 조합을 포함할 수 있다. 약제학적으로 허용 가능한 담체는 조성물을 생체 내 전달에 적합한 것이면 특별히 제한되지 않으며, 예를 들면, Merck Index, 13th ed., Merck & Co. Inc. 에 기재된 화합물, 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로스 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 이용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한, 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주이용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당 분야의 적정한 방법으로 또는 Remington's Pharmaceutical Science(Mack Publishing Company, Easton PA, 18th, 1990)에 개시되어있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.The composition of the present invention may also include a carrier, diluent, excipient or a combination of two or more commonly used in biological preparations. The pharmaceutically acceptable carrier is not particularly limited as long as it is suitable for in vivo delivery of the composition, for example, Merck Index, 13th ed., Merck & Co. Inc. , saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components may be mixed and used. Customary additives may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate formulations for injection, such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets. Furthermore, it can be preferably formulated according to each disease or component by using an appropriate method in the art or by using a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).
본 발명의 조성물은 목적하는 방법에 따라 비 경구 투여(예를 들어 정맥 내, 피하, 복강 내 또는 국소에 주사 제형으로 적용)하거나 경구 투여할 수 있으며, 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설률 및 질환의 중증도 등에 따라 그 범위가 다양하다. 본 발명에 따른 조성물의 일일 투여량은 0.0001 ~ 10 ㎎/㎖이며, 바람직하게는 0.0001 ~ 5 ㎎/㎖이며, 하루 일 회 내지 수회에 나누어 투여하는 것이 더욱 바람직하다. The composition of the present invention may be parenterally administered (for example, intravenously, subcutaneously, intraperitoneally, or topically applied as an injection formulation) or orally, depending on the desired method, and the dosage may be determined by the patient's weight, age, sex, The range varies according to health status, diet, administration time, administration method, excretion rate, and severity of disease. The daily dosage of the composition according to the present invention is 0.0001 to 10 mg/ml, preferably 0.0001 to 5 mg/ml, and it is more preferable to divide the administration once or several times a day.
본 발명의 조성물의 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 통상적으로 사용되는 단순 희석제인 물, 액체 파라핀 이외에 다양한 부형제, 예컨대 습윤제, 감미제, 방향제, 보존제 등이 함께 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제, 좌제 등이 포함된다.Liquid formulations for oral administration of the composition of the present invention include suspensions, internal solutions, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, aromatics, and preservatives in addition to water and liquid paraffin, which are commonly used simple diluents etc. may be included. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, suppositories, and the like.
또한, 본 발명의 약학적 조성물은 기존의 코로나 바이러스 감염 치료용 조성물과 함께 투여함으로써, 코로나 바이러스 감염 치료 효과를 증가시킬 수 있다. 이때 병용 투여는 기존의 코로나 바이러스 감염 치료용 조성물과 동시에 또는 순차적으로 이루어질 수 있다.In addition, the pharmaceutical composition of the present invention can increase the treatment effect of coronavirus infection by administering together with the existing composition for treatment of coronavirus infection. In this case, the combined administration may be performed simultaneously or sequentially with the existing composition for treating coronavirus infection.
본 발명의 용아초 추출물의 용아초(Agrimonia pilosa)는 한방에서 예로부터 널리 사용된 약재로 어린순을 나물로 하고 한방에서 선초를 이질, 위궤양, 자궁출혈에 사용한다. 즉, 약학적 조성물 또는 건강기능식품 조성물로 사용할 경우에 일반적인 합성 화합물에 비하여 부작용이 덜할 수 있으므로, 안전하게 약학적 조성물 및 건강기능식품 조성물에 포함되어 유용하게 사용될 수 있다.Yongacho ( Agrimonia pilosa ) of the Yongacho extract of the present invention is a medicinal herb that has been widely used in oriental medicine since ancient times. That is, when used as a pharmaceutical composition or health functional food composition, side effects may be less than those of general synthetic compounds, so it can be safely included in pharmaceutical compositions and health functional food compositions and can be usefully used.
하기의 실시예를 통하여 본 발명을 보다 상세하게 설명한다. 그러나 하기 실시예는 본 발명의 내용을 구체화하기 위한 것일 뿐 이에 의해 본 발명이 한정되는 것은 아니다.The present invention will be described in more detail through the following examples. However, the following examples are only for specifying the content of the present invention, and the present invention is not limited thereto.
<준비예 1> 실험의 재료<Preparation Example 1> Material for experiment
DMEM(-/-), Overlay media(0.6% agarose in DMEM), 12 well plate, Vero E6, 1x PBS(Cell culture grade)을 사용하여 하기의 실험방법에 의해 실험을 진행하였다.DMEM (-/-), Overlay media (0.6% agarose in DMEM), 12 well plate, Vero E6, and 1x PBS (cell culture grade) were used to conduct the experiment according to the following experimental method.
<준비예 2> 용아초 추출물의 제조방법<Preparation Example 2> Manufacturing method of Yongacho extract
용아초(Agrimonia pilosa)의 잎은 서울의 BioKorea Co. LTd(Seoul)에서 구입하고, 바우처 표본(BMRI-RG-1601)은 한국 용인 경희대학교 바이오메디컬연구센터에 기탁하였다. 건조된 샘플(20 kg)을 80±2℃에서 6시간 동안 50% 에탄올로 추출한 다음 여과하였다. 그 후, 회전 증발기를 사용하여 농축시키고 동결건조하였다. 최종 생성물 수율은 용아초 1.57 kg이었다. 용아초 추출물은 사용전까지 4 ℃에서 보관하였다. 여기에서 상기 에탄올 50% 용아초 추출물은 물, 메탄올 10%, 메탄올 30%, 메탄올 50%, 메탄올 70%, 메탄올 90%, 에탄올 10%, 에탄올 30%, 에탄올 50%, 에탄올 70%, 에탄올 90% 추출물을 이용한 예비실험에서의 최적화된 농도로 하기 실험에서는 에탄올 50% 용아초 추출물을 이용하여 실험을 진행하였다.The leaves of Agrimonia pilosa were obtained from BioKorea Co. in Seoul. It was purchased from LTd (Seoul), and the voucher specimen (BMRI-RG-1601) was deposited at the Biomedical Research Center of Kyunghee University, Yongin, Korea. Dried samples (20 kg) were extracted with 50% ethanol at 80±2° C. for 6 hours and then filtered. It was then concentrated using a rotary evaporator and lyophilized. The final product yield was 1.57 kg of Yongacho. Yongacho extract was stored at 4 ℃ until use. Here, the
<실시예 1> 실험방법<Example 1> Test method
① Vero E6 cells을 12웰-플레이트에 3.0 x 105 cells/well로 seeding하고, ② 37℃, CO2 인큐베이터에서 배양하였다. ③ 상등액을 제거하고, 1x PBS로 2번 wash 단계를 진행하였다. ④ Pretreatment(추출, 37℃, CO2 인큐베이터, 2시간), ⑤ 상등액을 제거하고, 바이러스 흡착(virus adsorption) (50pfu/well, shake/10min), ⑥ 상등액을 제거하고, add 1.5㎖ overlay media containing extracts), ⑦ 3일(72시간) 뒤에 결과를 확인하였다.① Vero E6 cells were seeded in a 12-well plate at 3.0 x 10 5 cells/well, ② cultured in a 37°C, CO 2 incubator. ③ Remove the supernatant, and wash step twice with 1x PBS. ④ Pretreatment (extraction, 37℃, CO 2 incubator, 2 hours), ⑤ Remove supernatant, virus adsorption (50 pfu/well, shake/10min), ⑥ Remove supernatant, add 1.5㎖ overlay media containing extracts), ⑦ The results were confirmed after 3 days (72 hours).
<실시예 2> 용아초 추출물의 플라크 감소 분석 실험 - 1<Example 2> Plaque reduction assay of Yongacho extract - 1
현재 SARS-CoV-2의 치료 효과가 있다고 알려진 렘데시비르(Remdesivir, Rem)를 비교군으로 설정하여 동일 농도에 대하여 SARS-CoV-2의 플라크 감소 효과를 측정한 결과 도 1에서 나타낸 것과 같이 비교군보다는 약간 낮지만 농도의존적으로 플라크 감소 효과가 증가하는 것으로 나타났다.Remdesivir (Rem), which is currently known to have a therapeutic effect on SARS-CoV-2, was set as a comparison group to measure the plaque reduction effect of SARS-CoV-2 at the same concentration. Comparison as shown in Figure 1 Although slightly lower than the group, it was found that the plaque reduction effect increased in a concentration-dependent manner.
<실시예 3> 용아초 추출물의 플라크 감소 분석 실험 - 2<Example 3> Plaque reduction analysis experiment of Yongacho extract - 2
현재 SARS-CoV-2의 치료 효과가 있다고 알려진 비교군으로 렘데시비르(Remdesivir, Rem) 5 μM와 클로로퀴논 포스페이트(chloroquine phosphate, C.P) 10 μM을 사용하여 실험을 진행하였다. 도 2 내지 도 4에서 나타낸 것과 같이 용아초 추출물은 농도의존적으로 플라크 감소 효과가 우수하며, 고농도에서도 세포독성이 없이 항바이러스 효과를 나타냄을 알 수 있었고, 용아초 추출물을 고농도로 사용하는 경우에는 렘데시비르를 저농도 사용한 것보다 더 우수한 결과를 나타내었다. 도 4의 경우 바이러스 감염시간인 1시간동안 용아초 추출물을 동시 처리한 실험결과로, 용아초 추출물에 의해 바이러스 엔트리 자체가 억제되는 것을 확인하였다. 하기 표 1은 이에 대한 값을 수치로 나타낸 것이다.The experiment was conducted using 5 μM of Remdesivir (Rem) and 10 μM of chloroquine phosphate (CP) as a control group known to have a therapeutic effect on SARS-CoV-2. As shown in FIGS. 2 to 4, it was found that the yongacho extract has an excellent plaque reduction effect in a concentration-dependent manner, and exhibits an antiviral effect without cytotoxicity even at high concentrations. It showed better results than using low concentrations of desivir. In the case of FIG. 4, it was confirmed that the virus entry itself was inhibited by the Yongacho extract as an experimental result of simultaneous treatment with the Yongacho extract for 1 hour, which is the virus infection time. Table 1 below shows numerical values for this.
<실시예 4> 용아초 추출물의 바이러스 복제억제 실험<Example 4> Virus replication inhibition test of Yongacho extract
현재 SARS-CoV-2의 치료 효과가 있다고 알려진 비교군으로 렘데시비르(Remdesivir, Rem) 5 μM와 클로로퀴논 포스페이트(chloroquine phosphate, C.P) 10 μM을 사용하여 실험을 진행하였다. 도 5에서 나타낸 것과 같이 용아초 추출물은 농도의존적으로 바이러스의 스파이크 단백질 발현 RNA복제 억제효과가 우수하며, 고농도에서도 세포독성이 없이 항바이러스 효과를 나타냄을 알 수 있었고, 용아초 추출물을 고농도로 사용하는 경우에는 렘 데 시비르를 저농도 사용한 것보다 더 우수한 결과를 나타내었다.The experiment was conducted using 5 μM of Remdesivir (Rem) and 10 μM of chloroquine phosphate (CP) as a control group known to have a therapeutic effect on SARS-CoV-2. As shown in FIG. 5, it was found that the yongacho extract has an excellent effect of inhibiting viral spike protein expression RNA replication in a concentration-dependent manner, and exhibits an antiviral effect without cytotoxicity even at high concentrations. In some cases, results were better than those using low concentrations of remdesivir.
<실시예 5> 용아초 성분 우르솔산(ursolic acid) 및 케르세틴(quercetin)의 SARS-CoV-2 복제억제 실험<Example 5> Inhibition of SARS-CoV-2 replication by ursolic acid and quercetin
용아초 성분의 항바이러스 효과 검증을 위해, Vero E6 세포에 SARS-CoV-2를 감염시킨 후 용아초 성분에서 분리한 우르솔산(ursolic acid) 및 케르세틴(quercetin)을 처리하여 바이러스 복제억제 효능을 측정하였다. 그 결과 도 6와 같이 우르솔산(ursolic acid)는 각각 15.2%, 31.6%, 50.1%, 케르세틴(quercetin)은 각각 28.5%, 40.3%, 49.3%의 바이러스 복제억제 효과를 나타냈다.In order to verify the antiviral effect of the ingredients of Yongacho, Vero E6 cells were infected with SARS-CoV-2 and then treated with ursolic acid and quercetin isolated from the ingredients of Yongacho to measure the efficacy of inhibiting viral replication. did As a result, as shown in FIG. 6, ursolic acid exhibited 15.2%, 31.6%, and 50.1%, respectively, and quercetin, respectively, 28.5%, 40.3%, and 49.3% of viral replication inhibitory effects.
<실시예 6> 용아초 성분 우르솔산(ursolic acid) 및 케르세틴(quercetin)과 SARS-CoV-2 spike RBD의 molecular docking<Example 6> Molecular docking of ursolic acid, quercetin, and SARS-CoV-2 spike RBD
용아초 추출물이 SARS-CoV-2의 absorption을 방해하는 것으로 나타났기 때문에, viral spike RBD가 숙주세포에 결합하는 것을 용아초 성분에 의해 방해를 받을수 있다. 이에 용아초 성분인 우르솔산(ursolic acid) 및 케르세틴(quercetin) 구조에 SARS-CoV-2 spike receptor-binding domain(RBD)의 molecular docking을 분석하였다. 또한 SARS-CoV-2 spike RBD가 지속적으로 돌연변이를 일으켜 효율적인 백신 및 항바이러스 치료제 개발을 방해하기 때문에 SARS-CoV-2 spike RBD의 변형인 B.1.1.7 spike RBD에 대한 우르솔산(ursolic acid) 및 케르세틴(quercetin)의 결합 친화도를 분석하여, 우르솔산(ursolic acid) 및 케르세틴(quercetin)의 잠재적 항바이러스 효과를 평가하였다. Molecular docking 분석에서 계산된 결합 에너지는 하기 표 2과 같다. 우르솔산(ursolic acid)는 SARS-CoV-2 spike RBD와 B.1.1.7 spike RBD 모두 비슷한 수치를 나타냈으며, 케르세틴(quercetin)은 B.1.1.7 spike RBD에 더 안정한 것으로 나타났다. 이러한 결과는 용아초 추출물이 SARS-CoV-2 spike RBD 및 B.1.1.7 spike RBD 모두에 항바이러스 치료제로서의 잠재력을 가지고 있음을 나타낸다(도 7 참조).Since Yongacho extract has been shown to interfere with the absorption of SARS-CoV-2, the binding of the viral spike RBD to the host cell may be prevented by the Yongacho component. Therefore, the molecular docking of SARS-CoV-2 spike receptor-binding domain (RBD) was analyzed on the structures of ursolic acid and quercetin, which are components of Yongacho. In addition, ursolic acid for B.1.1.7 spike RBD, a variant of SARS-CoV-2 spike RBD, because SARS-CoV-2 spike RBD constantly mutates, hindering the development of effective vaccines and antiviral treatments. and the binding affinity of quercetin were analyzed to evaluate the potential antiviral effects of ursolic acid and quercetin. The binding energies calculated in the molecular docking analysis are shown in Table 2 below. Ursolic acid showed similar levels in both SARS-CoV-2 spike RBD and B.1.1.7 spike RBD, and quercetin was found to be more stable in B.1.1.7 spike RBD. These results indicate that the extract of Yongacho has potential as an antiviral treatment against both SARS-CoV-2 spike RBD and B.1.1.7 spike RBD (see Fig. 7).
<실시예 7> 용아초 추출물의 체온 상승 억제 효과 확인<Example 7> Confirmation of the effect of inhibiting the increase in body temperature of the dragon plant extract
고열 동물 모델에서 상기 준비예 2의 제조방법으로 제조된 용아초 추출물의 해열 효과를 확인하였다. 구체적으로, 실험에 사용된 Sprague-Dawley(SD) rats는 일주일간 사육실 환경에 적응시킨 후 사용하였다 사육실 온도는 25±1℃, 습도는 50~60%로 유지하였다. Light/dark cycle이 12시간 주기로 조절되게 한 후, 고형사료와 물을 제한 없이 공급하였다. 경희대학교 동물실험윤리위원회에서 제공한 지짐서의 원리에 의해서 동물실험을 수행하였다. In the high fever animal model, the antipyretic effect of the Yongacho extract prepared by the preparation method of Preparation Example 2 was confirmed. Specifically, Sprague-Dawley (SD) rats used in the experiment were used after being acclimated to the breeding room environment for a week. After the light/dark cycle was adjusted to a 12-hour cycle, solid feed and water were supplied without restriction. Animal experiments were conducted according to the principles of the guidelines provided by the Animal Experimentation Ethics Committee of Kyunghee University.
체온 상승 유발물질(lipopolysaccharides, LPS; sigma, USA) 2.5 mg/kg로 생리식염수에 녹여 상기 실험동물의 복강내로 투여하여 발열을 유발하였다. 실험군은 5마리씩 6군으로 발열 유발 30분 전에 용아초 추출물(25, 50, 100 mg/kg)과 양성대조군(indomethacin, INN, 100 mg/kg)를 경구투여하였다. 발열을 유발하기 전(0 h) 및 유발 6시간 후(6 h)에 직장 내 체온을 측정하여 도 8에 나타내었다.2.5 mg/kg of a body temperature increase inducing substance (lipopolysaccharides, LPS; sigma, USA) was dissolved in physiological saline and administered intraperitoneally to the experimental animals to induce fever. Experimental groups were divided into 6 groups of 5 animals, and 30 minutes before the onset of fever, Yongacho extract (25, 50, 100 mg/kg) and positive control group (indomethacin, INN, 100 mg/kg) were orally administered. Rectal body temperature was measured before (0 h) and 6 hours after (6 h) induction of fever, and is shown in FIG. 8 .
체온 상승 유발물질(LPS) 투여군은 투여 6시간 후 투여 전보다 체온이 상승하였다. 그러나 용아초 추출물를 투여한 군은 모두 농도의존적으로 체온 증가를 억제하는 것을 확인하였다. 이러한 결과로부터 용아초 추출물은 발열을 억제하는 해열 효능이 우수한 것을 확인하였다. In the body temperature increase inducer (LPS) administration group, the body temperature increased 6 hours after administration compared to before administration. However, it was confirmed that all of the groups administered with the Yongacho extract suppressed the increase in body temperature in a concentration-dependent manner. From these results, it was confirmed that the yongacho extract was excellent in antipyretic effect of suppressing fever.
상기 실시예들에 의해 본 발명의 용아초 추출물을 사용하여 SARS-CoV-2 바이러스에 대한 플라크 감소 실험을 진행한 결과 농도의존적으로 유의적인 결과를 확인하였다. 또한, SARS-CoV-2의 spike protein(스파이크 단백질)의 RNA 복제억제 실험을 진행한 결과 매우 우수하게 바이러스의 복제를 억제함을 확인하였다. 따라서, 용아초 추출물은 SARS-CoV-2의 RNA복제를 억제하여 코로나 바이러스를 억제하는 것으로 나타났다. 또한 체온 상승 유발물질로 유도된 고열에서도 용아초 추출물이 체온 상승을 억제하여 바이러스 감염에 의한 발열을 억제할 수 있을 것으로 생각된다. 이를 통하여 고농도에서 독성이 없으면서 치료효과가 우수한 코로나 바이러스 감염의 예방 또는 개선용 조성물의 개발이 가능할 것이며, 이를 통하여 코로나 바이러스의 예방, 개선 또는 치료용 조성물로서 추가 연구를 통해 건강기능식품 또는 의약품으로 개발 가능할 것이다. According to the above examples, as a result of the plaque reduction experiment for the SARS-CoV-2 virus using the yongacho extract of the present invention, significant results were confirmed in a concentration-dependent manner. In addition, as a result of conducting an RNA replication inhibition experiment of the spike protein of SARS-CoV-2, it was confirmed that the virus replication was inhibited very well. Therefore, it was shown that the extract of Yongacho suppresses the corona virus by inhibiting the RNA replication of SARS-CoV-2. In addition, even in high fever induced by substances that cause body temperature rise, it is thought that the extract of Yongacho can suppress the rise in body temperature and suppress fever caused by viral infection. Through this, it will be possible to develop a composition for preventing or improving corona virus infection that is non-toxic at high concentration and has excellent therapeutic effect, and through this, it is developed as a health functional food or medicine through additional research as a composition for preventing, improving or treating corona virus. It will be possible.
이상에서 살펴본 바와 같이, 본 발명의 구체적인 실시예를 상세하게 설명되었으나, 본 발명의 사상을 이해하는 당업자는 동일한 사상의 범위 내에서 다른 구성요소를 추가, 변경, 삭제 등을 통하여, 퇴보적인 다른 발명이나 본 발명 사상의 범위 내에 포함되는 다른 실시예를 용이하게 제안할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상술한 상세한 설명보다는 후술하는 특허청구의 범위에 의하여 나타내어지며, 특허청구의 범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.As described above, the specific embodiments of the present invention have been described in detail, but those skilled in the art who understand the spirit of the present invention may add, change, delete, etc. other components within the scope of the same idea, and other degenerate inventions. However, other embodiments included within the scope of the present invention can be easily suggested. Therefore, the embodiments described above should be understood as illustrative in all respects and not limiting. The scope of the present invention is indicated by the claims to be described later rather than the above detailed description, and all changes or modifications derived from the meaning and scope of the claims and equivalent concepts thereof are included in the scope of the present invention. should be interpreted as
Claims (11)
상기 용아초 추출물은 에탄올 및 물이 3:7 내지 7:3의 부피비로 혼합된 에탄올수용액으로 추출된 것인
SARS-CoV-2 감염의 예방 또는 치료용 약학적 조성물.Containing the extract of Yongacho as an active ingredient,
The yongacho extract is extracted with an aqueous ethanol solution in which ethanol and water are mixed in a volume ratio of 3:7 to 7:3
A pharmaceutical composition for preventing or treating SARS-CoV-2 infection.
상기 용아초 추출물은 SARS-CoV-2에 대한 플라크 감소 효과를 가지는 것인, SARS-CoV-2 감염의 예방 또는 치료용 약학적 조성물.According to claim 1,
The yongacho extract has a plaque reducing effect on SARS-CoV-2, a pharmaceutical composition for preventing or treating SARS-CoV-2 infection.
상기 용아초 추출물은 SARS-CoV-2 복제를 억제시키는 것인, SARS-CoV-2 감염의 예방 또는 치료용 약학적 조성물.According to claim 1,
The yongacho extract is to inhibit SARS-CoV-2 replication, a pharmaceutical composition for the prevention or treatment of SARS-CoV-2 infection.
상기 용아초 추출물은 우르솔산(ursolic acid) 또는 케르세틴(quercetin) 성분을 포함하는 것인, SARS-CoV-2 감염의 예방 또는 치료용 약학적 조성물.According to claim 1,
The yongacho extract is a pharmaceutical composition for the prevention or treatment of SARS-CoV-2 infection, which comprises ursolic acid or quercetin component.
상기 용아초 추출물은 SARS-CoV-2로 인한 발열을 억제하는 효과를 가지는 것인, SARS-CoV-2 감염의 예방 또는 치료용 약학적 조성물.According to claim 1,
The yongacho extract has an effect of suppressing fever due to SARS-CoV-2, a pharmaceutical composition for preventing or treating SARS-CoV-2 infection.
상기 조성물은 SARS-CoV-2 스파이크 단백질의 세포막 결합을 차단하여 감염을 억제하는 것인, SARS-CoV-2 감염의 예방 또는 치료용 약학적 조성물.According to claim 1,
The composition inhibits infection by blocking the cell membrane binding of the SARS-CoV-2 spike protein, a pharmaceutical composition for preventing or treating SARS-CoV-2 infection.
A health functional food composition for preventing or improving SARS-CoV-2 infection, comprising an extract of Yongacho as an active ingredient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200058555 | 2020-05-15 | ||
| KR1020200058555 | 2020-05-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210141341A KR20210141341A (en) | 2021-11-23 |
| KR102551499B1 true KR102551499B1 (en) | 2023-07-05 |
Family
ID=78695317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210049299A Active KR102551499B1 (en) | 2020-05-15 | 2021-04-15 | Composition for the prevention or treatment of SARS-CoV-2 infection, comprising the extract of Agrimonia pilosa as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102551499B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023008594A1 (en) * | 2021-07-26 | 2023-02-02 | 에이피알지 주식회사 | Composition for prevention or treatment of coronavirus (sars-cov-2) infection, comprising agrimonia pilosa extract as active ingredient |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102252302B1 (en) | 2018-11-09 | 2021-05-17 | 주식회사 레이크머티리얼즈 | Sublimation device for high purity semiconductor |
-
2021
- 2021-04-15 KR KR1020210049299A patent/KR102551499B1/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Microbiol. Immunol. 54, 11-19쪽(2010.) 1부.* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210141341A (en) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102204299B1 (en) | Therapeutic agent for coronavirus comprising Elaeocarpus sylvestris extract as effective component | |
| KR101317318B1 (en) | A composition comprising the extract of Galla Rhois or the compounds isolated therefrom showing inhibiting activity of novel influenza, avian influenza, or SARS syndrome | |
| KR101032066B1 (en) | Pharmaceutical composition for the prevention and treatment of colds comprising extracts of kojang-gun, fractions thereof or stilbene compounds | |
| KR101141314B1 (en) | Composition for immunopotentiating comprising the extract of herbal formula, Ojeok-san | |
| KR20170115852A (en) | Pharmaceutical Composition for Preventing or Treating Respiratory Disease Containing Mixed Herbal Extract | |
| KR101534616B1 (en) | Composition for Anti-Influenza Virus Comprising Penthorum chinense Pursh Extract | |
| KR102551499B1 (en) | Composition for the prevention or treatment of SARS-CoV-2 infection, comprising the extract of Agrimonia pilosa as an active ingredient | |
| KR101427096B1 (en) | Composition comprising extract of Dryopteris crassirhizoma or phloroglucinol derivatives isolated therefrom for treating or preventing Corona virus related disease | |
| KR102785593B1 (en) | Composition for preventing, alleviating or treating liver cancer comprising complex extract of Oplopanax elatus and Eclipta prostarata as effective component | |
| KR100675618B1 (en) | Composition for the prevention or treatment of asthma or allergic disease, including the extract of three hundred seconds | |
| KR102665503B1 (en) | Composition for the prevention or treatment of SARS-CoV-2 infection, comprising the extract of Galla rhois as an active ingredient | |
| EP2992890B1 (en) | Pharmaceutical composition for treatment of inflammatory bowel disease | |
| KR100760386B1 (en) | A composition for the prevention and treatment of arthritis, including the extract of the mixed herbal herbal medicine | |
| KR100818363B1 (en) | Health supplements for the prevention or improvement of inflammation and allergic diseases, including poison extracts | |
| KR100531633B1 (en) | Composition comprising the extract of Korean Phellinus linteus for the treatment and protection of cold or flu | |
| KR101906208B1 (en) | Pharmaceutical Composition for preventing or treating constipation comprising Liriope platyphylla extract, Glycyrrhiza uralensis Fischer and Chinese Liquorice as an active ingredient | |
| WO2023008594A1 (en) | Composition for prevention or treatment of coronavirus (sars-cov-2) infection, comprising agrimonia pilosa extract as active ingredient | |
| RU2780346C1 (en) | Therapeutic agent against coronavirus including an elaeocarpus sylvestris extract | |
| KR102738005B1 (en) | Composition for improving immunity or for antiviral | |
| KR102652245B1 (en) | Composition for Prophylaxis and Treatment of Osteoporosis Comprising Piperis Longi Fructus Extract | |
| EP4151226A1 (en) | Coronavirus therapeutic agent comprising zanthoxylum piperitum leaf extract as active ingredient | |
| KR20130059741A (en) | Pharmaceutical compositions for preventing or treating arthritis comprising euphorbia ebracteolata extracts | |
| CN106074824A (en) | Enhancing immunity and the compositions of prophylactic treatment influenza, preparation technology and purposes | |
| KR20240094160A (en) | Sanguisorba officinalis Linne extracts inhibiting the infection of the SARS-CoV-2 Delta variant | |
| KR20070087952A (en) | Composition for the prevention and treatment of arthritis comprising assorted herbal extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20210415 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230427 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230629 |
|
| PG1601 | Publication of registration |